Genomma Lab Valuation
| LABB Stock | MXN 26.30 0.14 0.54% |
At this time, the firm appears to be undervalued. Genomma Lab Internacional retains a regular Real Value of 29.11 per share. The prevalent price of the firm is 26.3. Our model calculates the value of Genomma Lab Internacional from evaluating the firm fundamentals such as Return On Asset of 0.0921, current valuation of 20.43 B, and Return On Equity of 0.13 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Genomma Lab's price fluctuation is very steady at this time. Calculation of the real value of Genomma Lab Internacional is based on 3 months time horizon. Increasing Genomma Lab's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Genomma Lab is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genomma Stock. However, Genomma Lab's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 26.3 | Real 29.11 | Hype 26.3 | Naive 25.42 |
The intrinsic value of Genomma Lab's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Genomma Lab's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Genomma Lab Internacional helps investors to forecast how Genomma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genomma Lab more accurately as focusing exclusively on Genomma Lab's fundamentals will not take into account other important factors: Genomma Lab Total Value Analysis
Genomma Lab Internacional is now anticipated to have takeover price of 20.43 B with market capitalization of 18.09 B, debt of 3.83 B, and cash on hands of 1.41 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Genomma Lab fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
20.43 B | 18.09 B | 3.83 B | 1.41 B |
Genomma Lab Investor Information
About 29.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.51. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Genomma Lab Internacional last dividend was issued on the 9th of November 2022. The entity had 2:1 split on the 3rd of August 2010. Based on the measurements of operating efficiency obtained from Genomma Lab's historical financial statements, Genomma Lab Internacional is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Genomma Lab Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genomma Lab has an asset utilization ratio of 71.89 percent. This suggests that the Company is making 0.72 for each dollar of assets. An increasing asset utilization means that Genomma Lab Internacional is more efficient with each dollar of assets it utilizes for everyday operations.Genomma Lab Ownership Allocation
Genomma Lab Internacional has a total of 1 Billion outstanding shares. Genomma Lab secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Genomma Lab Profitability Analysis
The company reported the revenue of 15.49 B. Net Income was 1.31 B with profit before overhead, payroll, taxes, and interest of 9.56 B.About Genomma Lab Valuation
Our relative valuation model uses a comparative analysis of Genomma Lab. We calculate exposure to Genomma Lab's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genomma Lab's related companies.Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico, the United States, and Latin America. Genomma Lab Internacional, S.A.B. de C.V. was founded in 1996 and is based in Mexico City, Mexico. GENOMMA LAB operates under Drug ManufacturersSpecialty Generic classification in Mexico and is traded on Mexico Stock Exchange. It employs 1451 people.
8 Steps to conduct Genomma Lab's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Genomma Lab's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Genomma Lab's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Genomma Lab's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Genomma Lab's revenue streams: Identify Genomma Lab's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Genomma Lab's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Genomma Lab's growth potential: Evaluate Genomma Lab's management, business model, and growth potential.
- Determine Genomma Lab's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Genomma Lab's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Genomma Stock Analysis
When running Genomma Lab's price analysis, check to measure Genomma Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomma Lab is operating at the current time. Most of Genomma Lab's value examination focuses on studying past and present price action to predict the probability of Genomma Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomma Lab's price. Additionally, you may evaluate how the addition of Genomma Lab to your portfolios can decrease your overall portfolio volatility.